dihexa metabolic stability compared to angiotensin iv

dihexa metabolic stability compared to angiotensin iv Small molecule activation of the neurotrophin hepatocyte growth factor treat Alzheimer disease Dihexa (also known as PNB-0408)

Name: dihexa metabolic stability compared to angiotensin iv Small molecule activation of the neurotrophin hepatocyte growth factor treat Alzheimer disease Dihexa (also known as PNB-0408)
Brand: psychiatrist-in-kuwait.com
SKU: 48950223958
Price: 20.03 USD
Availability: InStock
Rating: 4.1386 (5 reviews)

Dihexa (also known as PNB 0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the bloodbrain barrier and has shown synaptogenic effects in preclinical models. The often quoted The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases ScienceDirect Comparative bleeding risk between angiotensin II receptor blockers with high versus low P glycoprotein inhibitory activity in patients with atrial fibrillation receiving direct oral anticoagulants Hypertension Research Dihexa (PNB 0408) Angiotensin IV analogue CAS NO.:1401708 83 5 GlpBio DPP (Dipeptidyl Peptidase) 4 Inhibitor Attenuates Ang II (Angiotensin II)Induced Cardiac Hypertrophy via GLP (Glucagon Like Peptide) 1Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4 HDAC (Histone Deacetylase) 4

SKU: 48950223958 · From psychiatrist-in-kuwait.com

4.1

USD20.03 USD69.03

Pay in 4 interest-free payments of $5.01 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

On the basis of our validated device manufacturing, packaging and shelf-life stability results, BPCDX could be widely distributed and stored up to 2 years before use, providing an alternative to the paradigm of securing consent for donation, harvesting corneas postmortem, pathogen testing and short-term storage in accredited facilities (to a maximum of 7 days)

*Based on results from a 12-week third-party clinical study of 90 women aged 18-65, daily use of the product was shown to support hair regrowth following acute telogen effluvium **Based on consumer perception results from a 12-week third-party clinical study of 90 women aged 18-65, daily use of the product was shown to support hair regrowth following acute telogen effluvium